Imaging Biomarkers in Radiotherapy: Enhancing Precision and Personalization

This activity explores the evolving role of imaging biomarkers in radiotherapy, focusing on their capacity to improve target delineation, systemically predict and monitor treatment responses, and inform personalized clinical decision making on adaptive platforms. Advances in MRI, PET, and CT/CBCT modalities, coupled with quantitative imaging analyses and AI-driven analytics, are transforming cancer treatment by enabling greater personalization. Current key trends include leveraging functional and multiparametric imaging to reveal underlying tumor biology beyond structural morphology, the evolution of adaptive radiotherapy platforms that generate high quality, longitudinal imaging data, the growing integration of AI and radiomics to enhance prediction precision, and emerging use of molecular imaging probes to target tumor-specific pathways related to radiotherapy. Through a series of expert-led talks, attendees learn how these innovations in personalized treatment strategies are translating into improved patient outcomes with reduced toxicities. This activity also addresses potential challenges such as lack of standardization, validation and equitable access to cutting-edge technologies while fostering discussions on inclusive solutions in clinical and research settings.

Topics:

  1. Imaging Biomarkers in Precision Radiotherapy: Advances and Promise
    Xiangrong Qi, PhD, DABR, FAAPM
  2. Clinical Evidence and Utilization of Imaging Biomarkers in Radiotherapy
    Filippo Alongi, PhD, MD, RT
  3. Roadmap of Imaging Biomarkers in Radiotherapy: Current Frontiers, Challenges and Future Directions
    Issam El Naqa, PhD, DABR, FAAPM

This activity is available from June 2, 2026, through 11:59 p.m. Eastern time on June 1, 2028. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, physicists, radiation biologists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Examine the utility and untapped potential of imaging biomarkers across MRI, PET and CT in radiotherapy.
  • Discuss the role of adaptive platforms and AI in enhancing treatment precision. 
  • Understand the application of imaging biomarkers across different cancer disease sites. 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
06/02/2026
Course expires: 
06/01/2028
Cost:
$149.00
Rating: 
0

Moderators:  

  • Dandan Zheng, PhD, FAAPM, is employed by University of Rochester. Dr. Zheng owns stock in Eli Lilly. 
  • Anil Sethi, PhD, FAAPM, is employed by Loyola University Chicago. Dr. Sethi receives honoraria and travel expenses from Standard Imaging, Inc. and TARGIT Collaborative Group. 

Speakers:

  • Xiangrong Qi, PhD, DABR, FAAPM, is employed by UCLA School of Medicine. Dr. Qi receives grant/research funding from Varian, Inc.  
  • Filippo Alongi, MD, PhD, RT, is employed by IRCCS Sacro Cuore Don Calabria Hospital, University of Brescia. Dr. Alongi has no relevant financial relationship with ineligible companies to disclose. 
  • Issam El Naqa, PhD, DABR, FAAPM, is employed by Moffitt Cancer Center. Dr. El Naqa has no relevant financial relationship with ineligible companies to disclose. 

Planners:

  • Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 
     

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until June 1, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.